What is meant by atopic allergy
Kouadio Celestin Ahogo1, Yao Isidore Kouassi1, Ildevert Patrice Gbery1, Kouadio Richard Azagoh2, Kouame Issouf Yeboua1, Kouame Alexandre Kouassi1, Ange Sylvain Allou1
1Dermatology Service, Félix Houphouët Boigny University, CHU Treichville, Abidjan, Côte d’Ivoire, 2Pediatric service, Félix Houphouët Boigny University, CHU Treichville, Abidjan, Côte d’Ivoire
Corresponding author: Dr. Kouadio Celestin Ahogo, E-mail: [email protected]
Submission: 04.08.2017; Acceptance: 27.10.2017
Few studies own been devoted to atopic dermatitis in children in sub-Saharan Africa.
We therefore make this study in Côte d’Ivoire in order to contribute to a better knowledge of atopic dermatitis in children on black skin. In our study the prevalence was 9.2%. The duration of the disease before the consultation ranged from 3-45 days. Atopic dermatitis occurs more frequently in children from2 to 5 years ancient. More than half of the patients had a history of atopy and the lesions generally were localized in the folds.
60% of the lesions were dry and were trigged by dust. The pruritus was often insomnia and the scratching leads to hyperpigmentation of the lower eyelid; a characteristic sign on black skin not often reported in the literature.
Key words: Atopic dermatitis, Children, Black skin, Cote d’Ivoire
On epidemiologic stage, 70 cases of atopic dermatitis own been recorded out of a entire of 765 children seen in consultation. The prevalence of atopic dermatitis in children was 9.2%. 52.9% of the patients were male with a sex ratio (M/F)at 1.1.
The age of the children’s ranged from 6 months to 13 years. Children from 2 to 5 years represented 42.9% of the patients, followed by the age group from 6 to 13 years (30%). The duration of the disease before the consultation ranged from 3-45 days. Outbreaks of the disease were more than 15 days in 72.4% of cases.
A triggering factor was found in 15.7% of our patients, it was mainly dust (17.1%)and perfumes (5.7%). The personal and family histories of atopy are represented in Table I.
Table 1: Personal and family histories of atopy
The types of eczema observed were: dry (60%), oozing (32.9%), and lichenification (07.1%). These lesions were found in the folds (54.3%), the trunk (51.4%), the legs (31.4%), and the face (30%)with pigmentation of the lower eyelid (7.1%).
The scalp (22.9%)and generalized (02.9%).
Atopic dermatitis was minor in 57.1% of cases, moderate (40%), and severe (2.9%); the other signs of atopic dermatitis observed in children are represented in Table II. Complications were observed in 58.57% of children. These included insomnia pruritus (44.3%), bacterial (12.9%)and viral (1.4%)secondary infection.
Table 2: Other signs of atopic dermatitis
This article has been written by these authors, it has not been send or published by another journal.
70 cases of atopic dermatitis was observed among 765 pediatric dermatoses, the prevalence was therefore 9.2%.
In Western Europe, the prevalence of atopic dermatitis in children is between 10-20% [3,4]. The most affected age group in the study was 2 to 6 years. In fact, atopic dermatitis often begins duringthe first year of life (the new born)and decreases around the age of 5 years. 54.2% of the children had a history of atopic disease. These included allergic rhinitis (37.1%), asthma (25.7%)and allergic conjunctivitis (17.1%). Six (06)of our patients regularly developed a food allergy. The association of several atopic clinical signs in the same patient is classic but inconstant [5,6].
The duration of relapses was in 72.4% of cases longer than 15 days. This could be explained in our context by self-medication. In one-quarter of the patients dust (17.1%)was the triggerfactor. Atopic dermatitis is a multifactorial disease modulated by genetic and environmental influences [7,8]. Concerning the clinical aspects, atopic dermatitis in our study was predominantly in folds (54.3%). This predominance in folds was mostly observed in children over 2 years of age. As for the nursling, they had mainly facial lesions. Dry lesions (60%)were the most frequent, followed by oozing lesions (32.9%).
Seepage often represents an entry point for bacterial and viral complications of atopic dermatitis [9,10]. In fact, bacterial secondary infection occurred in 12.9% of cases. Lichenification was present in 7.1% of our patients.
Chronic scratching is the main factor of thisLichenification. Insomnia pruritus was found in 44.3% of our patients. Pruritus leads to sleep disturbances, sometimes with children’s growth retardation .
Instead, hyperpigmentation was observed on thelower eyelid (7.1%). This characteristic sign most visible on dark skin is due to chronic friction.
MATERIALS AND METHODS
This was a prospective study, with descriptive and analytical sight over 12 months. The target population waspatients seen in consultation over the period of our study. Boys and girls from 0 to 15 years with atopic dermatitis were included in the study.
Data from the study were collected on an inquiry sheet that included socio-demographic and clinical data.
Atopic dermatitis in Côte d’Ivoire occurs more frequently in children from 2 to 5 years ancient. More than half of the patients had a history of atopy and the lesions generally localized in the folds.
These were mainly dry lesions most often triggered by dust. The pruritus was often insomnia and the scratching lead to hyperpigmentation of the lower eyelid; a characteristic sign on black skin not often reported in the literature.
Atopic dermatitis or constitutional eczema generally occurs in children in a specific condition called atopy. Its pathophysiological, epidemiological, clinical and therapeutic aspects own been the subject of several studies in Europe and in America [1,2].
However, few studies own beendevoted to atopic dermatitis in sub-Saharan Africa. Therefore, we proposed to make this study in order to contribute to a better knowledge of atopic dermatitis in children, on black skin in Africa.
1.Catteau B. Atopic dermatitis:current epidemiology and clinical data. French J Allergol Clin Immunol. 2002;42:373-7.
2.Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical Signs of atopic dermatitis:A systematic review and recommendation.
J Allergy Clin Immunol. 2013;132:1337-47.
3.Taïeb A. Atopic dermatitis:definition, epidemiology, natural history, gravity and scores. Ann Dermatol Venereol. 2005132:35-43.
4.Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic dermatitis in children and adults:European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.
J Allergy Clin Immunol. 2006;118:152-69.
5.Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends In the prevalence of symptoms of asthma, allergic rhinitis conjunctivitis, and eczema in childhood:ISAAC Phases One and Three repeat multi-cross-sectional surveys. Lancet. 2006;368:733-43.
6.The prevalence of asthma, rhinitis and eczema in 13 to 14 years ancient children in Africa:The ISAAC Phase III. Allergy. 2007;3:247-58.
7.Borralevi T, Hubiche T, Léauté-Labrèze C, Saubusse E, Fayon M, Roul S, et al.
Epicutaneous aeroallergen sensitization in atopic dermatitis infants determine the role of epidermal barrier impairment. Allergy. 2008;63:205-10.
8.Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107:11971-5.
9.Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al.
Guidelines for the management of atopic dermatitis:section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-32.
10.Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin Atopic dermatitis. Genome Res.
11.Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased health care utilization. Pediatr Allergy Immunol. 2013;24:476-86.
Source of Support: Nil
Conflict of Interest: None declared.
Select a section on the left to see content.
<p>This section displays by default the canonical protein sequence and upon request every isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href=»http://www.uniprot.org/help/sequence_length»>length</a> and <a href=»http://www.uniprot.org/help/sequences»>molecular weight</a>.
The information is filed in diverse subsections. The current subsections and their content are listed below:<p><a href=’/help/sequences_section’ target=’_top’>More…</a></p>Sequencei
<p>This subsection of the <a href=»http://www.uniprot.org/help/sequences_section»>Sequence</a> section indicates if the <a href=»http://www.uniprot.org/help/canonical_and_isoforms»>canonical sequence</a> displayed by default in the entry is finish or not.<p><a href=’/help/sequence_status’ target=’_top’>More…</a></p>Sequence statusi: Complete.
O93972-1 [UniParc]FASTAAdd to basketAdded to basket« Hide 10 20 30 40 50
MVALKFAAVL SVVAAAVMAA PSSMDRRASP DNQVWVTSAS DYCLILPRHR
60 70 80 90 100
ESIGDSESPG RMRSFCSKPY DSSQGQINPG FWKEVHFKKT KNYVQLTGCI
110 120 130 140 150
NPRVQSTLLS HDDGGQYDSN GNGGVGNPEG SVCLGYSSYV ELVEPSDGKA
CIRCCVNDKY CDVGHDEDGC EAVIPGQYC
May 1, 2000 — v2
<p>This section is used to point to information related to entries and found in data collections other than UniProtKB.<p><a href=’/help/cross_references_section’ target=’_top’>More…</a></p>Cross-referencesi
Protein family/group databases
|Allergomei||3372 Mala s 8.0101
474 Mala s 8
Family and domain databases
ProtoNet; Automatic hierarchical classification of proteins
MobiDB: a database of protein disorder and mobility annotations
<p>This section provides general information on the entry.<p><a href=’/help/entry_information_section’ target=’_top’>More…</a></p>Entry informationi
| <p>This subsection of the ‘Entry information’ section provides a mnemonic identifier for a UniProtKB entry, but it is not a stable identifier.
Each reviewed entry is assigned a unique entry name upon integration into UniProtKB/Swiss-Prot.<p><a href=’/help/entry_name’ target=’_top’>More…</a></p>Entry namei
|<p>This subsection of the ‘Entry information’ section provides one or more accession number(s). These are stable identifiers and should be used to cite UniProtKB entries. Upon integration into UniProtKB, each entry is assigned a unique accession number, which is called ‘Primary (citable) accession number’.<p><a href=’/help/accession_numbers’ target=’_top’>More…</a></p>Accessioni||O93972Primary (citable) accession number: O93972|
| <p>This subsection of the ‘Entry information’ section shows the date of integration of the entry into UniProtKB, the date of the final sequence update and the date of the final annotation modification (‘Last modified’).
The version number for both the entry and the <a href=»http://www.uniprot.org/help/canonical_and_isoforms»>canonical sequence</a> are also displayed.<p><a href=’/help/entry_history’ target=’_top’>More…</a></p>Entry historyi
|Integrated into UniProtKB/TrEMBL:||May 1, 1999|
|Last sequence update:||May 1, 2000|
|Last modified:||December 11, 2019|
|This is version 31 of the entry and version 2 of the sequence. See finish history.|
|<p>This subsection of the ‘Entry information’ section indicates whether the entry has been manually annotated and reviewed by UniProtKB curators or not, in other words, if the entry belongs to the Swiss-Prot section of UniProtKB (<strong>reviewed</strong>) or to the computer-annotated TrEMBL section (<strong>unreviewed</strong>).<p><a href=’/help/entry_status’ target=’_top’>More…</a></p>Entry statusi||Unreviewed (UniProtKB/TrEMBL)|
Select a section on the left to see content.
<p>This section provides links to proteins that are similar to the protein sequence(s) described in this entry at diverse levels of sequence identity thresholds (100%, 90% and 50%) based on their membership in UniProt Reference Clusters (<a href=»http://www.uniprot.org/help/uniref»>UniRef</a>).<p><a href=’/help/similar_proteins_section’ target=’_top’>More…</a></p>Similar proteinsi